IBB240920P147000
- 0.20
- -0.65-76.47%
iShares Biotechnology ETF Newsroom
Sword of Justice! The US FTC sues three major pharmaceutical "middlemen", vows to correct the distorted profit chain.
The USA's FTC announced on its official website that it has filed a lawsuit against three major "pharmacy benefit managers" and their affiliated organizations, accusing them of engaging in anti-competitive and unfair kickback practices. FTC also "clearly stated" in the declaration its deep concern about the roles played by eli lilly and co, novo-nordisk a/s, sanofi, and other insulin pharmaceutical companies, and the competition bureau may recommend prosecuting these pharmaceutical companies in future enforcement actions.
Gilead Sciences Unusual Options Activity For September 20
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell as Investors Await Fed's Harker on Rate Cut
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
A Closer Look at 13 Analyst Recommendations For IQVIA Hldgs
IQVIA Hldgs Analyst Ratings
Behind the Scenes of Amgen's Latest Options Trends
Wells Fargo's 'Value Equity List' – Stocks With Potential That Trade at a Discount
'EMA Recommends Extending Indication Of Mpox Vaccine To Adolescents' - EMA
RBC Capital Reiterates Sector Perform on Vertex Pharmaceuticals, Maintains $431 Price Target
Vertex Pharmaceuticals Analyst Ratings
RBC Capital Reiterates Sector Perform on Moderna, Maintains $75 Price Target
Moderna Analyst Ratings
Biogen Analyst Ratings
Argenx's ADHERE Study Published In The Lancet Neurology, Showcasing VYVGART Hytrulo's Impact On Reducing CIDP Relapse And Disease Progression
Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
Looking Into Vertex Pharmaceuticals's Recent Short Interest
ICON Draws Bullish View at Leerink on Business Model
10 Health Care Stocks With Whale Alerts In Today's Session
UBS Highlights 30 Stocks Poised for Potential Moves After the Fed's Expected Rate Cut